Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

159 results about "Cell Surface Proteins" patented technology

Glycan-Tethered Stabiligases

Provided herein are novel stabiligases for use in cell membrane proteome analysis. The subject stabiligases are capable of attaching to glycans found on the surface of cell membranes to form glycan-tethered (GT) stabiligases. Such glycan-tethered stabiligases are capable of robustly and selectively attaching label probes to cell surface proteins of intact cells. The subject novel stabiligases described herein advantageously allow for the identification and profiling of cell membrane proteins that have undergone an extracellular N-terminal proteolytic event.
Owner:RGT UNIV OF CALIFORNIA

Rapid detection method for cytotoxic T cells in peripheral blood

The invention provides a rapid detection method for cytotoxic T cells in peripheral blood. Specifically, the method provided by the invention is used for rapidly identifying the cytotoxic T cells in the peripheral blood by detecting the expression of cell surface proteins CX3CR1 and GPR56. The method provided by the invention is quick to operate, does not involve cell fixation and membrane rupture, and does not affect cell activity.
Owner:MAGI CO LTD

Photosensitizing antibody-fluorophore conjugates

The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Phthalocyanine dye conjugate compositions

Provided are compositions containing a conjugate containing a phthalocyanine dye, including compositions containing stabilizing agents, such as non-ionic surfactants and / or protectants. In some aspects, the compositions result reduced aggregation of the conjugate due to agitation, temperature exposure, and / or pH. Also provided are articles of manufacture containing the compositions containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.
Owner:RAKUTEN MEDICAL INC

Methods for manufacturing phthalocyanine dye conjugates and stable conjugates

Provided are methods for manufacturing a conjugate containing a phthalocyanine dye, including methods that include one or more steps of preparing or producing the conjugate, formulating the conjugate and packaging the conjugate. In some aspects, the manufacturing methods result in the generation of a stable conjugate. Also provided are stable phthalocyanine dye conjugates, compositions and articles of manufacture containing the stable conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the phthalocyanine dye conjugates are conjugated to a targeting molecule, such as an antibody, that targets the conjugate to a cell or pathogen, such as by binding to a cell surface protein.
Owner:RAKUTEN MEDICAL INC

Glycan conjugate compositions and methods

The present disclosure provides methods and compositions for modulating cell surface proteins and receptor complexes using a novel class of glycan conjugates that can be used to engage the signaling pathways within desired c cell types. Such defined cell-targeting bioactive glyco-ligands are directed for cell engagement and activation in therapeutic applications.
Owner:CHILDRENS MEDICAL CENT CORP

Antibodies targeting CD318 (CDCP1) and uses thereof

CD318 (CDCP1) is a CUB-domain containing cell surface protein over-expressed in major types of cancers to promote tumor growth and metastasis. The present disclosure relates to the identification and characterization of novel anti-CD318 monoclonal antibodies. By targeting CD318 as a tumor associated antigen, the disclosure further relates to different modalities of using anti-CD318 antibodies to kill cancer cells, including CD318 antibody based immunocytokines, CD318 antibody-based immune modulators, and CD318 antibody drug conjugates.
Owner:TAVOTEK LAB INC +1

Cell analysis method, cell analysis device and storage medium

The invention relates to the technical field of cell analysis, and discloses a cell analysis method, a cell analysis device and a storage medium, and the method comprises the following steps: S1, multi-modal labeling: synchronously loading cell surface protein, a metabolism probe and a spatial positioning marker; s2, collaborative acquisition: obtaining space-time multi-dimensional data through flow type, mass spectrum and two-photon combination; s3, tensor modeling: constructing four-dimensional data and correcting spatial drift; s4, metabolic constraint decomposition: executing non-negative tensor decomposition to obtain a factor matrix; s5, dynamically adjusting parameters: optimizing excitation and sampling frequencies in real time according to factor changes; and S6, feature analysis: calculating a metabolism-phenotype coupling index. Through a multi-modal synchronous marking and four-dimensional dynamic tensor modeling method, cross-dimensional association of physical characteristics, molecular expression and metabolic activity is broken through, lossless fusion of single-cell multi-dimensional data is realized, and the spatial resolution is greatly improved compared with the prior art.
Owner:BEIJING JINGZHUN BIOTECHNOLOGY CO LTD

Precursory regulatory cytotrophoblast cells and uses thereof

To provide stem cell therapies for treating (curing) a variety of diseases or conditions, as an alternative to overcome certain shortcomings of existing embryonic stem cells and iPS cells.SOLUTION: Provided herein are: precursory regulatory cytotrophoblast cells produced in vitro and expressing specific cell surface proteins and combinations thereof; compositions thereof; and methods of treating disorders (e.g., cancers, inflammations, or autoimmune diseases) or conditions (e.g., skin conditions) by using the cells and compositions.SELECTED DRAWING: None
Owner:ACCELERATED BIOSCIENCES CORP

A dual DNA tetrahedron structure, its preparation method and application

The present invention provides a dual DNA tetrahedron structure, a preparation method and an application thereof. The dual DNA tetrahedron of the present invention includes a first DNA tetrahedron structure, a second DNA tetrahedron structure and a connecting chain. This structure can specifically recognize two cell surface proteins and be labeled by fluorescence; at the same time, due to the steric hindrance effect of the structure, it is difficult for the two proteins to approach each other, affecting the interaction between the two. This structure can exist on the cell surface for a long time, thus having a good cell regulation effect on these two cell membrane surface proteins, specifically reflected in reducing the phosphorylation level of HER2 protein, promoting the expression of apoptosis-related proteins, and ultimately leading to apoptosis of tumor cells and reducing the cell activity of tumor cells.
Owner:SHANDONG UNIV

Epitope engineering of CD38 cell surface receptors

Genetically engineered cells (e.g., HSPCs or T cells) having one or more genetically edited cell surface protein genes, such as hematopoietic stem cells, and therapeutic uses thereof, alone or in combination with immunotherapy targeting the cell surface proteins.
Owner:DANA FARBER CANCER INSTITUTE INC +1

Three-specificity immune cell adapter-cytokine fusion protein, and preparation method and application thereof

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.
Owner:NANJING DRUM TOWER HOSPITAL

Development of a novel therapeutic CD99 antibody to treat aggressive solid tumors in children

Methods, compositions, and systems for treating various cancers are disclosed. The disclosed compositions may include a poly peptide with affinity for a CD99 cell surface protein. Disclosed polypeptides may comprise a sequence selected from GYYMH, RINPYTGATTYNQIFKD, YYYGNNYNVYLDY, SASQGISNYLS, YTSTLHIS, and QQYSNLPWT, and may include mouse, human, or humanized peptide sequences. In many embodiments, the polypeptides may be immunoglobulins, for example IgG3 or IgG4. The disclosed polypeptides may be administered to a subject having a cancer cell with elevated expression of CD99. In some embodiments, the subject may be suffering from cancer, including diffuse intrinsic pontine glioma (DIPG). Ewing Sarcoma, acute myeloid leukemia (AML), ependymoma, or neuroblastoma. Treatment methods include administering the disclosed polypeptides to a subject that may also be treated with radiation. Disclosed herein are systems for treating one or more cancers. The systems may comprise a radiation source, for example a medical fractionated radiation source.
Owner:THE REGENTS OF THE UNIVERSITY OF COLORADO

Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Cytotoxicity targeting chimeras for CXCR3-expressing cells

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, or autoimmune diseases.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD

One-step enriched cell surface targeting cross-linking agent as well as preparation and application thereof

The invention relates to development and application of a one-step enriched cell surface targeting cross-linking agent. The cross-linking agent is TMTC13NHS-SO3-, and the chemical structural formula of the cross-linking agent is shown as a formula I. The chemical cross-linking agent has the following functional characteristics that in-situ cross-linking capture of protein on the surface of a living cell can be realized, and the chemical cross-linking agent has high biological compatibility, water solubility and cell membrane impermeability due to a bis-succinimide ester-sulfonate reactive active group. The chemical cross-linking agent is applied to the field of proteomics and provides important technical support for analysis of living cell surface protein complexes. # imgabs0 #
Owner:DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES

Hevamine-related plant compositions and methods

The present application relates to a compositions and methods comprising or expressing a hevamine A-related MoMo30 protein from Momordica balsamina. The MoMo30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients, and comprises an amino acid sequence of SEQ ID NO: 4. The MoMo30 protein and / or a nucleic acid encoding the same may be used in methods for preventing or treating microbial infections by HIV, SARS-CoV-2 and other enveloped viruses, as well as other microorganisms comprising cell surface proteins containing glycan residues, such as mannose.
Owner:MOREHOUSE SCHOOL OF MEDICINE

Cells expressing immunomodulatory molecules and systems expressing immunomodulatory molecules

Disclosed herein are immune cells (Bisuper Cells, BS-Cells) that have been engineered to express an immune cell activator polypeptide comprising an extracellular marker domain and incorporate the polypeptide into the cell membrane surface. Also disclosed are immune cells engineered to secrete one or more polypeptide effector molecules, and immune cells engineered to express both molecules. Nucleic acid vectors for expressing these molecules in immune cells are disclosed. Also disclosed are bispecific polypeptides that can be used to specifically bind immune cells expressing immune cell activator polypeptides to another cell. Also disclosed are systems comprising both immune cells and various bispecific polypeptides that can bind to different cell surface proteins of the same or different target cells, e.g., that can be used to expand immune cells in vivo and treat various tumors.
Owner:SHANGHAI CELL THERAPY GROUP CO LTD +1

Dual MHC-targeted T cell engager

Described herein are antigen binding proteins that include a Fab domain, a first pMHC binding domain, and a second pMHC binding domain that specifically bind to a cell surface protein of an immune cell. Also described are methods of treating cancer or viral infections with the antigen binding proteins.
Owner:CDR LIFE AG

Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same

Polynucleotide constructs and engineered natural killer (NK) cells expressing such constructs are provided for the treatment of cancer and other adenosine-overexpressing disease states. The constructs are a fusion of at least an antigen binding domain specific to an adenosine producing (or adenosine-intermediary producing) cell surface protein and a receptor for promoting cytotoxic or cytolytic activity of the NK cell upon activation, where activation occurs upon the antigen binding domain binding its target cell. Pharmaceutical compositions of the engineered NK cells are also provided, as well as methods of treating an adenosine overexpressing cancer using such pharmaceutical compositions.
Owner:PURDUE RES FOUND

Methods of reducing large granular lymphocyte and natural killer cell levels

The present disclosure relates to a method for treating diseases or disorders associated with LGL and / or NK cells using an antibody that binds to cell surface proteins on LGL and / or NK cells and possesses enhanced ADCC activity, a method for reducing or depleting LGL and / or NK cells, and a method for inducing ADCC activity. The present invention also relates to a method for reducing or depleting the number of macrogranulocytic lymphocytes and natural killer cells in human subjects upon administration of a CD94, CD57, or NKG2A binding molecule comprising a portion specifically binding to a CD94, CD57, or NKG2A receptor and an immunoglobulin Fc portion. In specific embodiments, the method of the present invention depletes or reduces the number of macrogranulocytic lymphocytes and natural killer cells in the spleen, blood, bone marrow, joints, or other tissues.
Owner:DREN BIO MANAGEMENT INC

Cell surface protein identification method

The present invention relates to a computer-implemented method for obtaining, by training, a tuned model configured to predict whether a protein is present at least partially on the external surface of a cell, a computer-implemented method for determining whether a protein is at least partially present on the external surface of a cell, a computer-implemented method for forming a dataset for obtaining, by training, the tuned model, and a system comprising a processor coupled to a memory and preferably a graphical user interface, the memory having recorded thereon the computer program comprising instructions for performing any of the computer-implemented methods.
Owner:WHITELAB GENOMICS

Overcoming antibody-interference in avians

The present invention provides a recombinant protein, and a recombinant vector expressing that protein, that can be used for the vaccination of seropositive avians, whereby the antibodies in the avian target are specific for an antigen comprised in that recombinant protein. By comprising in the recombinant protein also a domain that can bind to a cell surface protein on avian antigen presenting cells (APCs), the antigen is targeted to those APCs. It was found that this type of vaccine could safely overcome the negative effects of antibody interference, even after a single dose, even in very young avians, and even in the context of very high antibody levels.
Owner:INTERVET INC

Natural killer cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof

PCT designated stageWO2026177560A1DiseasePeripheral blood mononuclear cell
The present invention relates to NK cells expressing dual-targeting chimeric antigen receptors for CD19 and CD22, and uses thereof. In the present invention, it was found that the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent when, among the cell surface proteins of PBMCs for producing CAR-NK cells (UCI-101), CD16 is expressed at 70% or less, natural killer group 2D (NKG2D) is expressed at less than 10%, CD57 is expressed at 30% or less, low-density lipoprotein receptor (LDLR) is expressed at 0.1% or more, and natural cytotoxicity triggering receptor 3 (NKp30) is expressed at less than 10%. In addition, optimal conditions for inducing NK cell differentiation and optimal conditions for transduction, under which the delivery efficiency of a CAR expression vector and the production efficiency of CAR-NK cells are excellent, were established, and CAR-NK cells produced by the method according to the present invention were found to exhibit an excellent antitumor effect in an animal model, and thus can be effectively used as a composition for preventing or treating diseases related to CD22 (or CD19) expression or diseases related to B cells.

Compositions and methods for increasing secretion of molecules

Aspects herein relate, in part, to genetically modified bacteria capable of secreting protein of interest using signal peptides. Aspects herein also relate, in part, to presenting proteins of interest on a bacterial cell using truncated cell surface proteins.
Owner:UNIVERSITY OF CHICAGO

Glycan conjugate compositions and methods

The present disclosure provides methods and compositions for modulating cell surface proteins and receptor complexes using a novel class of glycan conjugates that can be used to engage the signaling pathways within desired cell types. Such defined cell-targeting bioactive glyco-ligands are directed for cell engagement and activation in therapeutic applications.
Owner:GANNA MERGER SUB INC

Rapid detection method for cytotoxic t cell in peripheral blood

PCT designated stageWO2026092297A1Cell dissociation methodsAntipyreticCX3CR1Cell activity
A rapid detection method for cytotoxic T cells in peripheral blood. The method enables rapid identification of cytotoxic T cells in peripheral blood by detecting the expression of T-cell surface protein CX3CR1, or CX3CR1 and GPR56. The detection method is rapid in operation, does not involve cell fixation and permeabilization, and does not affect cell activity.
Owner:SHANGHAI MAAGI MEDICAL TECH CO LTD

Methods for mass spectrometry analysis of engineered cell compositions

Provided herein are methods for generating a mass spectrometry (MS) profile of a sample from a cell composition, such as an engineered cell composition. In some embodiments, the mass spectrometry profile includes data based on one or more mass spectrometry analyses or techniques. Also provided herein are methods for, based on mass spectrometry profiles of one or more samples of such cell compositions: identifying a mass spectrometry (MS) profile of a genetically engineered cell composition comprising immune cells comprising a recombinant receptor by comparison to a reference mass spectrometry profile; characterizing a process for producing genetically engineered cell composition; assessing cell surface proteins of an engineered cell composition; and assessing a process for producing a genetically engineered cell composition.
Owner:JUNO THERAPEUTICS INC

Preparation and application of anti-cd38 rabbit recombinant monoclonal antibody

The application relates to preparation and application of anti-CD38 rabbit recombinant monoclonal antibodies, the obtained antibodies have good specificity, most importantly, the antibodies have high affinity and can recognize natural cell surface CD38 proteins, and can be used for flow, ELISA and immunohistochemical detection applications.
Owner:SUZHOU DIMA BIOTECHNOLOGY CO LTD